NEW YORK, June 23, 2020 /PRNewswire/ --BrainStorm Cell Therapeutics Inc.
NEW YORK, June 23, 2020 /PRNewswire/ --BrainStorm Cell Therapeutics Inc.
Leukemia are a heterogeneous group of cancers affecting the bone marrow and White Blood Cells (WBC). Leukemia is characterized by the rapid increase of abnormal blood cells growth or blasts, resulting in a decrease in the numbers of healthy, normal fully modified blood cells, leading to the typical symptoms of bleeding, anemia, and high risk of infection.
UK biotech startup Bit Bio has received 36.9M in Series A funding to boost the manufacturing efficiency of human cells for use in cell therapy and drug discovery.
THE HAGUE, Netherlands, June 13, 2020 /PRNewswire/ -- Sickle cell disease (SCD) and thalassemia are severe inherited blood disorders, often referred to as "hemoglobinopathies." They predominantly affect the Black and Asian ethnic minority populations in England. To ensure good standards and equitable access to care, the National Health Service in England has recently commissioned a model of regional care networks overseen by a new body, the National Haemoglobinopathy Panel. This organizational structure has enabled a rapid response to the COVID-19 epidemic and enabled collection of national data on new cases and outcomes to determine if hemoglobinopathy patients are at risk of adverse COVID-19 outcomes
-Beta thalassemia: Two patients are transfusion independent at 5 and 15 months after CTX001 infusion; data demonstrate clinical proof-of-concept for CTX001 in transfusion-dependent beta thalassemia- -Sickle cell disease: Patient is free of vaso-occlusive crises at 9 months after CTX001 infusion- -Five patients with beta thalassemia and two patients with sickle cell disease have been treated to date with CTX001 and all have successfully engrafted- ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, June 12, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new clinical data for CTX001, an investigational CRISPR/Cas9 gene-editing therapy, from the CLIMB-111 and CLIMB-121 Phase 1/2 trials in transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD), and highlighted recent progress in the CTX001 development program.
NEW YORK, June 11, 2020 /PRNewswire/ --BrainStorm Cell Therapeutics Inc.(NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Chaim Lebovits, CEO and Ralph Kern, MD, MHSc, President and Chief Medical Officer, will present a corporate overview on Thursday, June 18 at 9:00 am EST, during theRaymond James Human Health Innovations Conference, a virtual event connecting institutional investors with company management teams that will be held June 15-18, 2020.
Mesenchymal Stem Cells Market- Advances & Applications (2018) report provides 73 company profiles in each market niche, Identify the market segments that compose the MSC industry, Advanced Therapy Medicinal Products, Stem Cell Research Publications, Funding And Patents, Clinical Trials Involving MSCS.
Pivotal AUTO1 study in adult ALL patients enrolling Conference Call and Webcast to be held Friday, June 12, 2020 at 7:30 am EDT / 12:30 pm BST LONDON, June 12, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced new data highlighting progress on its AUTO1 program, the companys CAR T cell therapy being investigated in the ongoing ALLCAR Phase 1 study of relapsed / refractory adult B-Acute Lymphocytic Leukemia (ALL), at the European Hematology Association EHA25 Virtual Congress beginning June 11. AUTO1 in ALLAs of the data cut-off date of May 13, 2020, 19 patients had received AUTO1
Copenhagen, Denmark; June 4, 2020 Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for the subcutaneous (SC) formulation of DARZALEX (daratumumab), for the treatment of adult patients with multiple myeloma in all currently approved daratumumab intravenous (IV) formulation indications in frontline and relapsed / refractory settings. The approval follows a Positive Opinion by the CHMP of the European Medicines Agency (EMA) in April 2020.
Remestemcel-L, Mesoblasts lead candidate stem cell therapy for inflammatory diseases, improves lung function and exercise capacity in people with chronic obstructive pulmonary disease (COPD)and a high degree of inflammation, data from a post-hoc analysis of a Phase 2 trial show. Findings were presented in an oral presentation at the 2020 International Society for Cell & Gene Therapy (ISCT) annual meeting, which took place virtually May 2829
Recent Comments